Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM0GXWT)

Drug Name
ABP 654 Drug Info
Synonyms Ustekinumab biosimilar
Indication
Disease Entry ICD 11 Status REF
Plaque psoriasis EA90.0 Phase 3 [1]
Psoriatic arthritis FA21 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DM0GXWT

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-23 (IL23) TTC1GLB IL23A_HUMAN Not Available [2]
Interleukine 12 (IL-12) TTG68FB IL12A_HUMAN; IL12B_HUMAN Not Available [2]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Plaque psoriasis
ICD Disease Classification EA90.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-23 (IL23) DTT IL23A 5.37E-01 -0.1 -0.42
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04607980) A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Efficacy and Safety of ABP 654 Compared With Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Amgen